Cancer immunotherapy: using drugs and cells to exploit our immune systems

Friday 2 October 2015
A7, 3 hours

Organised by the FIP Hospital Pharmacy Section, the FIP Clinical Biology Section and the FIP SIG on Pharmacokinetics/Pharmacodynamics & Systems Pharmacology


This session will highlight emerging therapeutic approaches to modulate the immune system in the treatment of cancer. Pharmacists will be introduced to direct and indirect cell-based therapies for various cancer types as well as immunisation approaches with cancer vaccines. Although immunotherapy of cancer has a long history, only recently have new therapeutic modalities become approved for use in treating patients, and considerable research is underway to develop and evaluate novel approaches that exploit advances made in the fields of oncology and immunology at the molecular and systems levels. In addition to basic science, key issues of how these new potential therapies might be managed from a formulary perspective will be discussed, including considerations into how these treatments should be handled (and by whom) to assure safety, efficiency, and appropriate handling/disposal. 

Learning objectives

Knowledge-based session

At the conclusion of this session, participants will be able to:

  1. Describe current research and evidence supporting approaches to using antibodies, direct cell-based transfers, and vaccines to treat cancer.
  2. Identify the developmental challenges to bringing vaccine and cell-based immunotherapy to the patient bedside.
  3. Describe how translational approaches (such as mathematical and new experimental models) could be leveraged as evidence to expedite the development of promising immunotherapies.
  4. Identify the key issues associated with bringing these therapies into clinical formularies.

Chairs: Donald Mager (FIP Programme Committee and FIP SIG on PK/PD & Systems Pharmacology, USA) and Jim Stevenson (University of Michigan, USA)


09:00 1) Targeting programmed cell death-1 (PD-1)
R. Donald Harvey (Emory University, USA)

09:40 2) Bispecific T-cell engaging antibodies for cancer therapy
Andreas Wolf (Amgen Research, Germany)

10:20 Break

10:40 3) Translational modelling of anti-cancer vaccines
Iñaki Troconiz (University of Navarra, Spain)

11:20 4) Implementation of cell-based therapies in clinical practice
Ross McKinnon (Flinders University, Australia)